S. N. Markovic

883 total citations
25 papers, 618 citations indexed

About

S. N. Markovic is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. N. Markovic has authored 25 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. N. Markovic's work include Immunotherapy and Immune Responses (6 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cutaneous Melanoma Detection and Management (3 papers). S. N. Markovic is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cutaneous Melanoma Detection and Management (3 papers). S. N. Markovic collaborates with scholars based in United States, United Kingdom and Belgium. S. N. Markovic's co-authors include David J. Inwards, Ivana N. Micallef, Luis F. Porrata, Thomas M. Habermann, Joseph P. Colgan, Steven M. Ansell, Kay M. Ristow, Patrick B. Johnston, T. E. Witzig and G. S. Nowakowski and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Clinical & Experimental Immunology.

In The Last Decade

S. N. Markovic

24 papers receiving 607 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. N. Markovic United States 8 352 203 184 123 88 25 618
Seong Hyun Jeong South Korea 17 362 1.0× 104 0.5× 226 1.2× 216 1.8× 147 1.7× 67 761
Gan‐di Li China 13 342 1.0× 141 0.7× 371 2.0× 128 1.0× 81 0.9× 65 641
S. Petrasch Germany 17 194 0.6× 187 0.9× 125 0.7× 81 0.7× 125 1.4× 36 642
Paolo Fiumara Italy 12 282 0.8× 205 1.0× 303 1.6× 196 1.6× 58 0.7× 28 684
Anjum Hassan United States 16 168 0.5× 88 0.4× 220 1.2× 100 0.8× 92 1.0× 39 540
Calogero Vetro Italy 14 215 0.6× 184 0.9× 120 0.7× 225 1.8× 41 0.5× 60 675
Yuji Nakafusa Japan 16 285 0.8× 154 0.8× 121 0.7× 148 1.2× 332 3.8× 50 782
Hiromichi Yamane Japan 15 491 1.4× 101 0.5× 206 1.1× 183 1.5× 112 1.3× 85 865
B. Vasseur France 12 522 1.5× 129 0.6× 166 0.9× 149 1.2× 63 0.7× 34 887
Radovan Vrḫovac Croatia 15 253 0.7× 157 0.8× 227 1.2× 223 1.8× 48 0.5× 65 810

Countries citing papers authored by S. N. Markovic

Since Specialization
Citations

This map shows the geographic impact of S. N. Markovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. N. Markovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. N. Markovic more than expected).

Fields of papers citing papers by S. N. Markovic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. N. Markovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. N. Markovic. The network helps show where S. N. Markovic may publish in the future.

Co-authorship network of co-authors of S. N. Markovic

This figure shows the co-authorship network connecting the top 25 collaborators of S. N. Markovic. A scholar is included among the top collaborators of S. N. Markovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. N. Markovic. S. N. Markovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vaidya, Rakhee, Thomas M. Habermann, J H Donohue, et al.. (2013). Bowel perforation in intestinal lymphoma: incidence and clinical features. Annals of Oncology. 24(9). 2439–2443. 100 indexed citations
2.
Markovic, S. N., et al.. (2011). Adjuvant GM-CSF therapy for patients with resected stage III/IV melanoma: A retrospective review of a single-center experience.. Journal of Clinical Oncology. 29(15_suppl). 8596–8596. 3 indexed citations
3.
Porrata, Luis F., Kay M. Ristow, Joseph P. Colgan, et al.. (2011). Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 97(2). 262–269. 162 indexed citations
4.
Allred, Jacob B., William J. Maples, Edward T. Creagan, et al.. (2010). N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM).. Journal of Clinical Oncology. 28(15_suppl). 8572–8572. 3 indexed citations
5.
Block, Matthew S., S. N. Markovic, Donald W. Northfelt, et al.. (2010). MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas.. Journal of Clinical Oncology. 28(15_suppl). TPS113–TPS113. 1 indexed citations
6.
Markovic, S. N., Lori A. Erickson, Thomas J. Flotte, et al.. (2010). Metastatic Malignant Melanoma. PubMed. 144(1). 405–425. 6 indexed citations
7.
Desai, Neelam V., Osmond J. D’Cruz, Xue Lin, et al.. (2010). Effect of plasma SPARC on outcome in cancer models.. Journal of Clinical Oncology. 28(15_suppl). 10600–10600. 1 indexed citations
8.
9.
O’Day, Steven, Jeff Sosman, Alexander C. Peterson, et al.. (2009). 23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma. European Journal of Cancer Supplements. 7(3). 13–13. 26 indexed citations
10.
Markovic, S. N., Vera J. Suman, Lisa A. Kottschade, et al.. (2009). A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E. Journal of Clinical Oncology. 27(15_suppl). 9055–9055. 2 indexed citations
11.
Desai, Neil, Daniel J. Knauer, José Iglesias, et al.. (2009). 1004 SPARC may be a predictive biomarker of response to nab-paclitaxel. European Journal of Cancer Supplements. 7(2). 88–88. 4 indexed citations
12.
Porrata, L.F., David J. Inwards, S. Ansell, et al.. (2008). 89: Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study. Biology of Blood and Marrow Transplantation. 14(2). 35–35. 2 indexed citations
13.
Croghan, Gary A., Francis Nichols, Wendy K. Nevala, et al.. (2008). VEGF A, C, and D levels in malignant pleural effusions. Journal of Clinical Oncology. 26(15_suppl). 22126–22126. 2 indexed citations
14.
Kumar, Surendra, Randolph S. Marks, Ronald L. Richardson, et al.. (2008). A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination with bortezomib in patients with advanced malignancy. Journal of Clinical Oncology. 26(15_suppl). 2569–2569. 3 indexed citations
15.
S̄pitler, Lynn E., Robert Weber, Scott Cruickshank, et al.. (2008). Granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) as adjuvant therapy of melanoma. Journal of Clinical Oncology. 26(15_suppl). 20006–20006. 1 indexed citations
16.
Wheatley, K., Natalie Ives, A.M.M. Eggermont, et al.. (2007). Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. Journal of Clinical Oncology. 25(18_suppl). 8526–8526. 99 indexed citations
17.
Block, Matthew S. & S. N. Markovic. (2007). The clinical experience of cancer vaccines for malignant melanoma. 142(2). 149–160. 3 indexed citations
18.
João, Cristina, Luis F. Porrata, Edwin A. Burgstaler, et al.. (2006). Immunologic autograft engineering by manipulation of apheresis machine collection settings. Biology of Blood and Marrow Transplantation. 12(2). 105–105. 2 indexed citations
19.
20.
Rao, Ruta, S. N. Markovic, & Pete Anderson. (2003). Aerosol Therapy for Malignancy Involving the Lungs. Current Cancer Drug Targets. 3(4). 239–250. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seong Hyun Jeong Breakdown of academic impact, for papers by Gan‐di Li Breakdown of academic impact, for papers by S. Petrasch Breakdown of academic impact, for papers by Paolo Fiumara Breakdown of academic impact, for papers by Anjum Hassan Breakdown of academic impact, for papers by Calogero Vetro Breakdown of academic impact, for papers by Yuji Nakafusa Breakdown of academic impact, for papers by Hiromichi Yamane Breakdown of academic impact, for papers by B. Vasseur Breakdown of academic impact, for papers by Radovan Vrḫovac
Rankless by CCL
2026